- (941) 248-3873
- support@peptide.partners
- 10am to 5pm ET, M-F
This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.
Swipe right to view full table →
Save over 70%!
 |
Peptide Sciences | Liberty Peptides | |
| Cost per milligram | $3.80 – $5.20 | $8.33 | $7.20 |
| Purity | 99.84% | 99.3% | 99.14% |
| Certified Endotoxin-safe | Yes | No | No |
| Independently Tested | Yes | No | No |
(For educational purposes only)
Sermorelin is a synthetic peptide that functions as an analog of growth hormone-releasing hormone (GHRH), designed to stimulate the body’s natural production of growth hormone. This 29-amino acid peptide represents the biologically active N-terminal fragment of the full 44-amino acid human GHRH molecule. Though it was once FDA-approved for diagnostic and therapeutic applications in pediatric growth disorders, sermorelin is no longer available as an approved drug product in the United States but may still be obtained through compounding pharmacies under certain circumstances.
Molecular Structure and Biochemical Properties
Sermorelin is a precisely designed synthetic peptide with specific biochemical characteristics that enable its growth hormone-stimulating functions.
Chemical Composition
Sermorelin is comprised of 29 amino acids in the sequence YADAIFTNSYRKVLGQLSARKLLQDIMSR, which corresponds to the first 29 amino acids of the natural human GHRH[1][2]. The full chemical designation is sermorelin acetate, the acetate salt of an amidated synthetic peptide[1]. This structure gives the compound its specific properties:
The N-terminal sequence of GHRH is remarkably conserved across several mammalian species, including humans, pigs, and cattle, highlighting its evolutionary importance[2]. Despite containing only the first 29 amino acids of the natural 44-amino acid hormone, sermorelin retains the full biological activity needed to stimulate growth hormone secretion.
Pharmacokinetic Profile
Sermorelin displays distinctive pharmacokinetic properties that influence its clinical application:
These properties necessitate specific administration protocols to achieve therapeutic effects, despite the peptide’s rapid clearance from circulation.
Mechanism of Action
Sermorelin operates through specific receptor-mediated pathways to stimulate growth hormone production and release.
Receptor Binding and Signaling
The primary mechanism of action involves direct interaction with specialized receptors in the anterior pituitary:
This mechanism preserves the natural pulsatile pattern of growth hormone secretion, which may offer advantages over direct growth hormone replacement.
Physiological Effects
The stimulation of endogenous growth hormone production leads to several physiological responses:
By working through the body’s natural pathways, sermorelin potentially offers a more physiological approach to growth hormone augmentation compared to direct GH administration.
Historical Clinical Applications
Sermorelin has been used in various clinical contexts, though its approved applications in the United States have changed over time.
FDA-Approved Uses
When previously available as an approved drug (marketed as Geref), sermorelin had specific sanctioned uses:
The FDA granted sermorelin acetate orphan drug designation in 1988 for “Treatment of idiopathic or organic growth hormone deficiency in children with growth failure,” and it received marketing approval in September 1997[7]. However, the manufacturer withdrew the product from the U.S. market in November 2002, and it is no longer available as an FDA-approved medication[3].
Off-Label Applications
Beyond its previously approved uses, sermorelin has been investigated for several potential applications:
These applications reflect growing interest in growth hormone modulation for both medical and wellness purposes, though clinical evidence supporting these uses varies considerably.
Current Regulatory Status
The regulatory landscape surrounding sermorelin has evolved significantly since its initial approval.
Current Approval Status
As of 2025, sermorelin is not FDA-approved for any indication in the United States[6]. While it was previously marketed under the trade name Geref by Serono Laboratories, the FDA now lists it as a “discontinued drug product”[3]. Important regulatory milestones include:
This change in status significantly affects how patients can legally access the compound.
Availability and Prescription Pathways
Despite lacking FDA approval, sermorelin may still be legally available through specific channels:
Patients seeking sermorelin treatment must typically complete a structured evaluation process, including comprehensive medical assessment, laboratory testing, and detailed health history review before receiving a prescription.
Administration and Dosing
Specific administration protocols are recommended for sermorelin therapy to maximize effectiveness and minimize side effects.
Delivery Methods
Sermorelin is typically administered through subcutaneous injection:
The subcutaneous route is preferred due to the peptide’s poor oral bioavailability, as digestive enzymes would rapidly degrade the peptide if taken orally.
Recommended Dosing
Standard dosing recommendations for sermorelin include:
The evening administration schedule takes advantage of the body’s natural circadian rhythm of growth hormone production, which typically peaks during early sleep phases.
Safety Profile and Adverse Effects
Understanding sermorelin’s safety profile is essential for appropriate risk assessment and patient monitoring.
Common Side Effects
The most frequently reported adverse effects of sermorelin include:
Most of these effects are mild to moderate in severity and often diminish with continued treatment as the body adapts to the therapy.
Drug Interactions
Sermorelin may interact with several medications, potentially affecting either its efficacy or the action of concomitant drugs:
These potential interactions highlight the importance of comprehensive medication review before initiating sermorelin therapy and throughout the treatment course.
Special Considerations
Certain patient populations and conditions warrant particular attention when considering sermorelin:
Regular monitoring through laboratory testing and symptom tracking helps identify any developing concerns and allows for timely intervention when necessary.
Conclusion
Sermorelin represents an interesting approach to growth hormone modulation that works through stimulating the body’s endogenous production rather than providing exogenous hormone replacement. As a synthetic 29-amino acid fragment of growth hormone-releasing hormone, it binds to specific receptors in the pituitary gland to promote natural growth hormone secretion in a pulsatile pattern.
Despite its previous FDA approval for treating growth hormone deficiency in children and for diagnostic evaluation of pituitary function, sermorelin is no longer available as an approved drug product in the United States. The manufacturer voluntarily withdrew it from the market in 2002, and its regulatory exclusivity expired in 2004. Currently, sermorelin can only be legally obtained through compounding pharmacies with a valid prescription from a licensed healthcare provider.
The compound’s extremely short half-life of 11-12 minutes necessitates specific administration protocols, typically involving daily subcutaneous injections at bedtime to align with natural hormone production patterns. While generally well-tolerated, sermorelin may cause injection site reactions, headaches, nausea, and other side effects, and can interact with several common medications.
As research continues into growth hormone modulation and its effects on aging, metabolism, and physical performance, sermorelin remains a compound of interest for both clinical researchers and healthcare practitioners focused on hormonal optimization. However, its limited regulatory status and the emergence of newer growth hormone secretagogues present ongoing challenges to its widespread clinical application.
⁂
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.
